Filter Results
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
69 Clinical Trials near Omaha, NE
Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
VK4-116 for Opioid Use Disorder
Overland Park, KansasThis first-in-human, randomized, double-blind, placebo-controlled, single ascending dose (SAD), phase I study is designed to assess the safety, tolerability and pharmacokinetics of VK4-116 in healthy volunteers in fasted and fed state.
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 1
Age:18 - 60
Sex:All
48 Participants Needed
Oral Dexmedetomidine for Pediatric Anesthesia
Kansas City, MissouriThe objective of this preliminary study is to assess the utility of oral dexmedetomidine as the sole sedative agent in pediatric population undergoing MRI.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 1
Age:3 - 6
Sex:All
18 Participants Needed
Imaging Techniques for Chronic Rejection
Iowa City, IowaThis studies purpose is to confirm the efficacy and efficiency of using OE-MRI and MRI with hyperpolarized gas techniques and Iodinated contrast CT scan, this will enhance understanding of CLAD pathophysiology. Moreover, this project is foundational to performing additional studies to establish if novel MRI imaging can serve as an objective confirmatory diagnostic tool for CLAD in post-transplant patients.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18 - 80
Sex:All
100 Participants Needed
BMS-986460 for Healthy Subjects
Lenexa, KansasThe purpose of this study is to assess the safety, tolerability, drug levels, and relative bioavailability of alternate formulations of BMS-986460 in healthy adult male participants.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 1
Age:18 - 60
Sex:Male
56 Participants Needed
MK-8527 + FTC/TDF for Healthy Subjects
Lincoln, NebraskaThe goal of this study is to learn what happens to MK-8527 in a healthy person's body over time, called a pharmacokinetic (PK) study. Researchers want to learn if there is a difference in the healthy person's body when MK-8527 is taken as a single dose (Treatment A) or with the medication Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) (Treatment B).
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:19 - 55
Sex:All
Key Eligibility Criteria
Disqualifiers:Low Bone Density, Renal Impairment, Autoimmune Disorders, Cancer, Others
20 Participants Needed
INCB000631 for Healthy Adults
Lincoln, NebraskaThis study will be conducted to assess the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics, and Food Effect of INCB000631 When Administered Orally to Healthy Adult Participants.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:19 - 55
Sex:All
Key Eligibility Criteria
Disqualifiers:Cardiovascular Disease, Hypertension, Autoimmune, Others
Must Not Be Taking:CYP3A4 Inhibitors, Others
84 Participants Needed
Adagrasib for Healthy Subjects
Lenexa, KansasThis is a study to evaluate bioequivalence between adagrasib reference tablets and high drug load tablets in healthy adult participants.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 60
Sex:All
Key Eligibility Criteria
Disqualifiers:Cardiac Disease, Gastrointestinal Conditions, Others
150 Participants Needed
Ceftibuten-ledaborbactam Etzadroxil for Healthy Subjects
Lenexa, KansasThis is a Phase 1, open-label, two-part, study in approximately 46 healthy adult participants between 18 and 55 years of age (both inclusive) (at least 16 participants in Part 1 and up to 30 participants in Part 2). The study will be conducted at one clinical site in the United States. Participants in Part 1 and Part 2 may be conducted in parallel. The duration of an individual participation will be approximately 46 days for Part 1 and 43 days for Part 2. All participants will be screened within 28 days prior to dosing. They will be admitted to the clinical research unit (CRU) the day prior to dosing and will remain in the CRU until the end of the PK sample collection period. All participants will return to the clinic for follow-up assessments 7 days ± 1 day after the last dose of study intervention.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18 - 55
Sex:All
46 Participants Needed
Flu Vaccine for Influenza
Kansas City, MissouriThe purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular injection of different formulations of a hexavalent influenza messenger ribonucleic acid (mRNA) vaccine composed of differing dose levels of trivalent (TIV) mRNA hemagglutinin (HA) in combination with TIV mRNA-neuraminidase (NA) compared to an active control ((Fluzone standard-dose quadrivalent influenza vaccine (QIV-SD) or Fluzone high-dose quadrivalent influenza vaccine (QIV-HD) in adults 50 years of age and older.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:50+
Sex:All
1158 Participants Needed
Bupivacaine vs BKK Combination for Pain Management After CIED Procedures
Overland Park, KansasThis trial is testing a combination of three drugs to manage pain in patients undergoing heart device implant surgeries. The goal is to provide better pain relief than the current standard and avoid using opioids.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
200 Participants Needed
The primary objective of this study is to investigate the effect of multiple-dose administration of carbamazepine on the pharmacokinetics of S-892216 in healthy adults.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 55
Sex:All
16 Participants Needed
mRNA Vaccine for Flu
Omaha, NebraskaThe purpose of this study is to evaluate a pandemic flu H5 strain messenger ribonucleic acid (mRNA) vaccine at 3 dose levels (low, medium, and high) in comparison with placebo in 276 healthy adult participants to select the adequate dose for further clinical development.
The duration per participant will be approximately 13 months.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:18+
Sex:All
276 Participants Needed
EBV Vaccine for Healthy Adults
Omaha, NebraskaEpstein Barr virus (EBV) is a virus which can cause infectious mononucleosis and is associated with certain kinds of cancer and multiple sclerosis. Researchers are looking for new ways to prevent disease related to EBV and have developed a new study vaccine (V350A and V350B). The main goal of this study is to learn about the safety and tolerability of V350A and V350B in healthy adults.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 30
Sex:All
Key Eligibility Criteria
Disqualifiers:Infectious Mononucleosis, Immunosuppressive Conditions, Others
Must Not Be Taking:Immunosuppressants
200 Participants Needed
TBD11 Safety Study in Healthy Adults
Lincoln, NebraskaThis is a randomized, double-blind, placebo controlled First in human (FIH) trial of TBD11, administered to healthy adults. The trial will be conducted in two parts. Part 1 will consist of single ascending dose (SAD) and Food effect (FE) cohorts, and Part 2 will consist of multiple ascending dose (MAD) cohorts.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:19 - 55
Sex:All
Key Eligibility Criteria
Disqualifiers:Cardiovascular Disease, Cancer, Drug Abuse, Others
Must Not Be Taking:Opioids, Amphetamines
108 Participants Needed
NX-5948 Bioavailability Study in Healthy Subjects
Lincoln, NebraskaThis is a 2-cohort, fixed-sequence, 3-period, relative bioavailability, food-effect, and drug-drug interaction study. It is an open-label study evaluating the relative bioavailability of NX-5948 tablets compared to capsules, and the effect of food and an acid-reducing agent on the pharmacokinetics (PK) of NX-5948.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:19 - 55
Sex:All
Key Eligibility Criteria
Disqualifiers:Psychiatric, Cardiovascular, Gastrointestinal, Others
18 Participants Needed
BGB-53038 for Cancer
Kansas City, KansasThis is a first-in-human (FIH), open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BGB-53038 as monotherapy in participants with advanced or metastatic solid tumors harboring KRAS mutations or amplification, as well as when used in combination with tislelizumab (also known as BGB-A317) in participants with nonsquamous non-small cell lung cancer (NSCLC) and used in combination with cetuximab in participants with colorectal cancer (CRC). The study consists of 2 phases: Phase 1a Dose Escalation and Safety Expansion and Phase 1b Dose Expansion.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:KRAS G12R Mutation, Brain Metastasis, Hepatitis, Others
Must Not Be Taking:Anti-RAS Treatments
177 Participants Needed
UTI Vaccine for Urinary Tract Infections
Lenexa, KansasThe purpose of this study is to assess safety, reactogenicity, and immune response of the candidate UTI vaccine compared to placebo in adults between and including 18-64 years of age (YOA), and to perform a preliminary evaluation of clinical efficacy in females between and including 18-64 YOA.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18 - 64
Sex:All
Key Eligibility Criteria
Disqualifiers:Immunodeficient, Neurological Disorders, Others
Must Not Be Taking:Antibiotics, Methenamine, D-mannose
448 Participants Needed
V540B Vaccine for HPV Prevention
Omaha, NebraskaResearchers are looking for new ways to prevent cancers related to human papillomavirus (HPV). HPV is a common virus that can cause an infection. There are many different types of HPV. Most people's immune system can fight HPV infection and it goes away without treatment. For some people, HPV infections can last longer and may cause cancer years later.
A standard vaccine to prevent HPV-related cancers is GARDASIL®9 (G9). G9 protects against 9 types of HPV but it does not protect against other types of HPV. The study vaccine (called V540B) is designed to protect against the same HPV types that G9 protects against plus other HPV types. The main goal of this study is to learn about the safety of V540B in healthy adults and if people tolerate it.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 45
Sex:All
Key Eligibility Criteria
Disqualifiers:Abnormal Pap Smears, Genital Lesions, Cancer, Others
72 Participants Needed
Combination Vaccine for Flu and COVID-19
Omaha, NebraskaThis study will evaluate the reactogenicity, safety, and immune response of Flu Seasonal/SARS-CoV-2 mRNA (mRNA Flu/COVID-19) combination vaccine. The flu portion will target multiple strains of the flu virus, while the COVID-19 part will focus on the spike protein of the SARS-CoV-2 virus. Both parts of this vaccine have been tested individually before. This will be the first study to test the combined vaccine in humans in healthy adult participants.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:18+
Sex:All
780 Participants Needed
Flu and COVID-19 Vaccines for Virus Protection
Omaha, NebraskaThis study is to learn about flu and COVID vaccines, either alone or when mixed together. Healthy people aged 18 or older can join. Participants will get one shot in each arm, either a flu or COVID vaccine, alone or mixed. The study lasts about 6 months, and participants need to visit the research site at least 3 times.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:18+
Sex:All
1353 Participants Needed
NX-5948 Study in Healthy Subjects
Lincoln, NebraskaThis is a Phase 1, 2-period, open-label, single-dose, fixed-sequence study to assess the absolute bioavailability, absorption, metabolism, excretion, and mass balance of \[14C\]-NX-5948. Period 1 will analyze PD (pharmacodynamics) and exploratory biomarkers. Period 2 will analyze total radioactivity and metabolite profiling.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:19 - 55
Sex:Male
8 Participants Needed
KT-621 for Healthy Participants
Lincoln, NebraskaThis is a first-in-human study to evaluate safety, pharmacokinetics, and pharmacodynamics of single and multiple dose levels of KT-621 in healthy male and female adult participants.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:19 - 55
Sex:All
Key Eligibility Criteria
Disqualifiers:Respiratory, Gastrointestinal, Renal, Others
120 Participants Needed
FTX-101 for Healthy Subjects
Overland Park, KansasThis is a Phase 1, first-in-human (FIH), single-center, randomized, double-blind, placebo-controlled study in healthy male subjects. The study will include the following 2 parts:
* Part A: Single Ascending Dose (SAD) in healthy male subjects
* Part B: Multiple Ascending Dose (MAD) in healthy male subjects
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 59
Sex:Male
Key Eligibility Criteria
Disqualifiers:Cardiovascular, Gastrointestinal, Neurological, Others
Must Not Be Taking:QT Prolonging Drugs, St. John's Wort
80 Participants Needed
Negative Pressure Therapy for Surgical Wounds
Kansas City, KansasThe goal of this clinical trial is to evaluate the safety of the investigational device, Regenn® Negative Pressure Therapy System (Regenn® Therapy), a form of Negative Pressure Wound Therapy (NPWT), in the post-operative surgical wounds of patients undergoing lumbar spinal fusion surgeries. The main questions the study aims to answer are:
* The device-related serious adverse event rate.
* Patient post-operative pain as assessed using a validated pain measurement scoring system.
* The number and type of adverse events.
* The rate of delayed seroma formation.
Participants will
* Be screened for their suitability to participate in the investigational study using questions about their health, medical history, and current medications.
* Undergo a physical exam, an assessment of patient vital signs and routine blood analyses.
* Complete an Informed Consent Form if selected to participate in the investigational study.
* Be randomly assigned to the different study arms.
* Not change the operation of their respective device or to disturb components of their device.
* Notify their surgeon or designated healthcare provider should they have any questions or encounter any issues with their device.
* Attend two post-operative visits at approximately one month and three months.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 80
Sex:All
Key Eligibility Criteria
Disqualifiers:Hepatic Insufficiency, Autoimmune Diseases, Others
Must Not Be Taking:Steroids, Immunosuppressants
30 Participants Needed
mRNA Vaccine for RSV
Omaha, NebraskaThe purpose of this study is to assess the reactogenicity, safety and immune response of various formulations of the RSV mRNA investigational vaccine administered in healthy participants 18-45 years of age.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18 - 45
Sex:All
210 Participants Needed
Drug Interaction Study in Healthy Subjects
Lenexa, KansasThe Purpose of the Study is to Assess the Drug Interaction and Bioavailability of BMS-986278 in Tablet Formulations and the Effect that Food has on BMS-986278 in Tablet Formulation in Healthy Participants
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 65
Sex:All
73 Participants Needed
SP-624 for Major Depression
Lincoln, NebraskaThe main goal of this clinical trial is to learn if the active study drug (code name: SP-624) has any effect on the electrical activity of the brain in adult healthy volunteers and in adults with major depression. Another goal of the study is to learn if SP-624 improves memory and learning in adults with major depression. The study will also provide additional information on the safety of SP-624 and how well it is tolerated in adult healthy volunteers and adults with major depression.
Researchers will compare SP-624 to a placebo (a look-alike substance that contains no drug) to see if SP-624 has any effect on study tests.
Study participants will:
Take capsules of study drug (SP-624 or a placebo) once daily for 2 weeks; visit the clinic at Screening, Day 1 (first dose of study drug), and Day 15 (last dose of study drug) for checkups and tests; and have phone call check-ups on Day 7 and about 1 week after the last dose of study drug.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 60
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Breastfeeding, Significant Health Condition, Others
36 Participants Needed
NX-5948 for Healthy Subjects
Lincoln, NebraskaThis is a Phase 1, 2-part double-blinded (with respect to NX-5948/placebo), placebo-controlled study. Part 1 is a randomized, 3 period cross-over food-effect (FE) and drug-drug interaction (DDI) study. Part 2 is a single-period PK evaluation study.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18 - 55
Sex:Male
32 Participants Needed
MRT-6160 for Healthy Subjects
Lincoln, NebraskaThe principal aim of this study is to obtain safety and tolerability data when MRT-6160 is administered orally as single and multiple doses to healthy subjects. This information, together with the pharmacokinetic (PK) data, will help establish the doses and dosing regimen suitable for future studies in patients.
The study drug, MRT-6160, is experimental. This is the first study in which MRT-6160 will be given to humans.
Part 1: Subjects will receive a single oral dose of MRT-6160 or placebo on Day 1
Part 2: Subjects will receive multiple oral doses of MRT-6160 or placebo for 7 consecutive days
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:19 - 65
Sex:All
76 Participants Needed
BMS-986470 for Sickle Cell Disease
Lenexa, KansasThe purpose of this study is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, pH and food effect, and preliminary efficacy of BMS-986470 in healthy volunteers and participants with sickle cell disease.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Severe VOCs, Acute Chest Syndrome, Others
Must Be Taking:Hydroxyurea
184 Participants Needed
Page 1 of 3+
Frequently Asked Questions
How much do clinical trials in Omaha, NE pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
How do clinical trials in Omaha, NE work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across trials in Omaha, NE 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Omaha, NE is 12 months.
How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Omaha, NE several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Do I need to be insured to participate in a medical study in Omaha, NE ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
What are the newest clinical trials in Omaha, NE ?
Most recently, we added VK4-116 for Opioid Use Disorder, Oral Dexmedetomidine for Pediatric Anesthesia and Imaging Techniques for Chronic Rejection to the Power online platform.